In a Substack newsletter, Dr. William Makis cited a paper from 2020 (by Juarez et al) on the antitumor effects of ivermectin at clinically feasible concentrations where it was found to support its clinical development as a repositioned cancer drug.
According to the study, at a human dose of two mg/kg, ivermectin can achieve anti-cancer effects such as cell cycle arrest (inhibit proliferation), preferential inhibition of cancer stem-like cells, synergize with several chemotherapy drugs and inhibit tumor growth in a breast cancer mouse model.
It also found that the most sensitive cancer cell lines were the ovarian, breast, glioblastoma (brain), lung, colon, uterine squamous cell carcinoma (SCC), hepatocellular, triple-negative breast cancer (TNBC), pancreatic and endometrial.
NEW ARTICLE: IVERMECTIN Tested against 28 types of Cancer - which cancers were most sensitive to Ivermectin?
A research group from Mexico investigated Ivermectin in Cancer Paper: 2020 (Juarez et al) - Antitumor effects of ivermectin at clinically… pic.twitter.com/xWhgEBa1uv FDA took down social media posts discouraging ivermectin use for COVID-19 but mainstream media seemed to have missed this Back in March, the U.S. Food and Drug Administration (FDA) agreed to permanently take down its social media posts urging people to avoid the usage of ivermectin for COVID-19.
"Ivermectin has a preferential depletion effect on the cancer stem-like cell population," the authors included in the research.
Ivermectin was tested at two mg/kg/day, translating to roughly 5uM in vitro concentration.
https://www.naturalnews.com/2024-08-30-ivermectin-overcome-chemo-resistant-mrna-caused-cancers.html
No comments:
Post a Comment